Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

ARSYNL Rx vs NuuVim

ARSYNL Rx
Graded #348

Lower grade

vs+11.999999999999993
NuuVim
Graded #101

Higher grade

The verdict

NuuVim takes it — 71.1/100 to 59.1/100.

NuuVim grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. NuuVim is a Texas-based DTC telehealth program offering compounded semaglutide and tirzepatide in both injectable and oral forms — oral access is uncommon here — plus limited brand-name Ozempic and Zepbound.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueNuuVim +54
43
97
Dose & formulationNuuVim +32
64
96
Clinical oversightARSYNL Rx +36
78
42
Labs & monitoringARSYNL Rx +3
53
50
FulfillmentARSYNL Rx +2
63
61
Contract termsEven
55
55
ARSYNL Rx · left barNuuVim · right bar

The numbers

MetricARSYNL RxNuuVim
WeighScore59.1/10071.1/100
GradeCC
Scorecard rank#348#101
Semaglutide$233/mo (compounded)$79/mo (all doses, compounded)
Tirzepatide$366/mo (compounded)$133/mo (all doses, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyYes
ARSYNL Rx

Graded #348 · C

Strengths

  • Offers compounded semaglutide and tirzepatide, including a needle-free tirzepatide hypospray option
  • Veteran-founded telehealth with clinician-prescribed, personalized treatment
  • Multi-service platform — also covers hair restoration, TRT, sexual health, and longevity
  • Medications shipped discreetly to your home

Where it loses points

  • Pricing is not shown until you select a product (product pages sit behind a bot-verification gate)
  • Compounded GLP-1s are not FDA-approved finished products
  • Compounding pharmacy partner and exact state coverage are not disclosed on the site
  • No LegitScript certification visible on the accessible pages
NuuVim

Graded #101 · C

Strengths

  • Low compounded entry pricing — semaglutide from $79/mo, tirzepatide from $133/mo, flat all-dose pricing
  • Both injectable and oral compounded options for semaglutide and tirzepatide (oral access is uncommon)
  • LegitScript Certified and HIPAA-compliant
  • Two named compounding pharmacy partners (Hallandale Pharmacy and Pharmacy Hub), both vetted in our directory
  • Operating legal entity disclosed: NuuVim LLC, Texas governing law

Where it loses points

  • No founder, CEO, medical director, or pharmacist-in-charge named
  • Refund and cancellation policy not surfaced on the site
  • Compounded medications are not FDA-approved
  • Doesn't disclose which pharmacy fills which drug or form
  • FDA issued this company a warning letter dated 19 March 2025; the letter is public in FDA's warning-letter database

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard